<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808950</url>
  </required_header>
  <id_info>
    <org_study_id>SP848-nBCC-1104</org_study_id>
    <nct_id>NCT01808950</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma</brief_title>
  <official_title>Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirig Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirig Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is the observation and description of the preliminary efficacy of
      resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      efficacy assessments:

        -  Histopathological findings based on the biopsies of the primary tumor location and the
           tissue excision at the end of trial (histological cure).

        -  Description of the clinical-therapeutic effect of resiquimod on nBCC (nodular-basal cell
           carcinoma) by visual inspection (clinical evaluation of treatment area and assessment of
           complete clinical clearance)

        -  RNA-analysis (analysis of gene expressions for cytokines, cytotoxic and apoptotic
           signals)

        -  Investigator's global judgment of efficacy by means of a 7-point scale

      Safety assessments:

        -  Evaluation of Adverse Events (AEs) and Serious Adverse Events (SAEs)

        -  Evaluation of local tolerability (local skin reactions as erythema, edema,
           erosion/ulceration, exsudate, dryness, encrustation) by means of symptom scoring scales
           (0 = absent, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe).

        -  Evaluation of systemic tolerability [hematology (erythrocytes, leucocytes including
           neutrophils, hemoglobin, hematocrit, thrombocytes), blood chemistry (alkaline
           phosphatase, bilirubin, aspartate transaminase (ASAT), alanine transaminase (ALAT),
           serum creatinine), vital signs]. The thresholds concerning laboratory abnormalities that
           determine patient's discontinuation from trial were predefined upfront.

        -  Evaluation of the number of patients withdrawn from the trial

        -  Investigator's global judgment of tolerability by means of a 6-point scale

        -  Photographic documentation of the treatment area

      Exploratory parameter:

        -  C-reactive protein (CRP)

        -  Interferon-alpha, interleukin-6, interleukin-12, interferon-gamma, TNF-alpha
           (up-regulation of gene expression)

        -  Immunohistochemistry and characterization of cell types (CD8, T-cells, macrophages,
           dendritic cells)

        -  In addition, blood serum samples will be preserved and frozen for later tests that will
           be specified to the patients. The preserved material will be stored for a maximum of 2
           years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    safety issues
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological Cure Rate</measure>
    <time_frame>8 weeks after a maximal treatment period of 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Clinical Clearance Rate</measure>
    <time_frame>8 weeks after the 4 weeks treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Local Tolerability by Means of 5-point Scales</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>local skin reactions as erythema, edema, erosion/ulceration, exudate, dryness, encrustation judged by investigator by means of 5-point scales (0 = absent, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Systemic Tolerability Based on Haematology and Blood Chemistry Values and Vital Signs</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Judgment of Tolerability by Investigator by Means of a 6-point Scale</measure>
    <time_frame>8 weeks after a maximal treatment period of 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Nodular Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>0.06% Resiquimod Gel - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.06% Resiquimod Gel - B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.06% Resiquimod Gel - C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.06% Resiquimod Gel - A</intervention_name>
    <description>single 60mg dose</description>
    <arm_group_label>0.06% Resiquimod Gel - A</arm_group_label>
    <other_name>CD11301</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.06% Resiquimod Gel - B</intervention_name>
    <description>single 100mg dose</description>
    <arm_group_label>0.06% Resiquimod Gel - B</arm_group_label>
    <other_name>CD11301</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.06% Resiquimod Gel - C</intervention_name>
    <description>shave biopsy of BCC followed by single 100mg dose</description>
    <arm_group_label>0.06% Resiquimod Gel - C</arm_group_label>
    <other_name>CD11301</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed consent form.

          -  Male or non-pregnant, non-lactating female, â‰¥ 18 years.

          -  Must have a previously untreated, histologically confirmed nBCC on head, neck, trunk
             or arms.

          -  nBCC must not be larger than 20 mm in diameter and must be less than 5 mm in depth.

          -  Willing and able to participate in the trial as an outpatient and comply with all
             trial requirements.

        Exclusion Criteria:

          -  nBCC located close to or at mouth or eyes.

          -  Patients who have had an organ transplant.

          -  Known autoimmune disorder (especially psoriasis), impaired immune system (e.g. HIV),
             known thyroid abnormalities, known depression.

          -  An open wound or an infection in treatment area.

          -  Dermatological disease or condition (e.g. rosacea, atopic dermatitis, eczema) in the
             treatment or surrounding area that might impair trial assessments.

          -  Evidence of an active infection or systemic cancer.

          -  Flu or flu-like symptoms (including general indisposition, fever, nausea, muscle pain,
             chills) within a week before start of the trial.

          -  Known allergy or hypersensitivity to any of the trial gel ingredients.

          -  Evidence of unstable or uncontrolled clinically significant medical conditions as
             determined by the investigator (e.g., renal or hepatic disease).

          -  Current alcohol abuse or chemical dependency as assessed by the investigator.

          -  Patient who is detained or committed to an institution by a law court or by legal
             authorities.

          -  Participation in another clinical trial within one month before start of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R Dummer, PrMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Dermatolgy Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hauttumorcentrum CharitÃ© (HTCC)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <results_first_submitted>December 3, 2015</results_first_submitted>
  <results_first_submitted_qc>May 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 22, 2016</results_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.06% Resiquimod Gel - A</title>
          <description>60 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
0.06% Resiquimod Gel - A</description>
        </group>
        <group group_id="P2">
          <title>0.06% Resiquimod Gel - B</title>
          <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
0.06% Resiquimod Gel - B</description>
        </group>
        <group group_id="P3">
          <title>0.06% Resiquimod Gel - C</title>
          <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed
0.06% Resiquimod Gel - C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.06% Resiquimod Gel - A</title>
          <description>60 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
0.06% Resiquimod Gel - A</description>
        </group>
        <group group_id="B2">
          <title>0.06% Resiquimod Gel - B</title>
          <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
0.06% Resiquimod Gel - B</description>
        </group>
        <group group_id="B3">
          <title>0.06% Resiquimod Gel - C</title>
          <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed
0.06% Resiquimod Gel - C</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Histological Cure Rate</title>
        <time_frame>8 weeks after a maximal treatment period of 4 weeks</time_frame>
        <population>data were not collected for any of study participant.</population>
        <group_list>
          <group group_id="O1">
            <title>0.06% Resiquimod Gel - A</title>
            <description>60 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
0.06% Resiquimod Gel - A</description>
          </group>
          <group group_id="O2">
            <title>0.06% Resiquimod Gel - B</title>
            <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
0.06% Resiquimod Gel - B</description>
          </group>
          <group group_id="O3">
            <title>0.06% Resiquimod Gel - C</title>
            <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed
0.06% Resiquimod Gel - C</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Cure Rate</title>
          <population>data were not collected for any of study participant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Clinical Clearance Rate</title>
        <time_frame>8 weeks after the 4 weeks treatment period</time_frame>
        <population>data were not collected for any of study participant.</population>
        <group_list>
          <group group_id="O1">
            <title>0.06% Resiquimod Gel - A</title>
            <description>60 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation</description>
          </group>
          <group group_id="O2">
            <title>0.06% Resiquimod Gel - B</title>
            <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation</description>
          </group>
          <group group_id="O3">
            <title>0.06% Resiquimod Gel - C</title>
            <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed
0.06% Resiquimod Gel - C: shave biopsy of BCC followed by single 100mg dose</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Clinical Clearance Rate</title>
          <population>data were not collected for any of study participant.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Local Tolerability by Means of 5-point Scales</title>
        <description>local skin reactions as erythema, edema, erosion/ulceration, exudate, dryness, encrustation judged by investigator by means of 5-point scales (0 = absent, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe).</description>
        <time_frame>up to 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Systemic Tolerability Based on Haematology and Blood Chemistry Values and Vital Signs</title>
        <time_frame>up to 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Judgment of Tolerability by Investigator by Means of a 6-point Scale</title>
        <time_frame>8 weeks after a maximal treatment period of 4 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>0.06% Resiquimod Gel - A</title>
          <description>60 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
0.06% Resiquimod Gel - A</description>
        </group>
        <group group_id="E2">
          <title>0.06% Resiquimod Gel - B</title>
          <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
0.06% Resiquimod Gel - B</description>
        </group>
        <group group_id="E3">
          <title>0.06% Resiquimod Gel - C</title>
          <description>100 mg gel
Once daily prior to normal sleeping hours
5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed
0.06% Resiquimod Gel - C</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mutlilocular BCC right had Prox.</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nodular BCC arm left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>superficial BCC submammary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>exertional dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cornu cutaneum</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator is granted a right to publish and present Trial Results together with other investigators of Trial and to be referred to in publications containing such results. However, investigator shall not publish or present Trial Results unless Investigator has submitted to Spirig a draft of the intended publication or presentation for review and approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Francine Santoro</name_or_title>
      <organization>Galderma Spirig</organization>
      <phone>+41623878720</phone>
      <email>francine.santoro@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

